Drugs for Menopausal Symptoms
March 4, 2024 (Issue: 1697)
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection....more
- The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022; 29:767. doi:10.1097/gme.0000000000002028
- The North American Menopause Society (NAMS) 2023 Nonhormone Therapy Position Statement Advisory Panel. The 2023 nonhormone therapy position statement of the North American Menopause Society. Menopause 2023; 30:573. doi:10.1097/gme.0000000000002200
- CJ Crandall et al. Breast cancer, endometrial cancer, and vascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause 2018; 25:11. doi:10.1097/gme.0000000000000956
- JA Simon et al. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis. Menopause 2023; 30:855. doi:10.1097/gme.0000000000002211
- Ospemifene (Osphena) for dyspareunia. Med Lett Drugs Ther 2013; 55:55.
- Prasterone (Intrarosa) for dyspareunia. Med Lett Drugs Ther 2017; 59:149.
- DL Barton et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Cancer Care 2018; 26:1335. doi:10.1007/s00520-017-3960-9
- CJ Crandall et al. Management of menopausal symptoms: a review. JAMA 2023; 329:405. doi:10.1001/jama.2022.24140
- RT Chlebowski et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA 2020; 324:369. doi:10.1001/jama.2020.9482
- J Jin. Treatment of menopause symptoms with hormone therapy. JAMA 2022; 327:1716. doi:10.1001/jama.2022.5105
- JL Shifren et al. Menopausal hormone therapy. JAMA 2019; 321:2458. doi:10.1001/jama.2019.5346
- RH Cobin et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update. Endocr Pract 2017; 23:869. doi:10.4158/ep171828.ps
- VA Flores et al. Hormone therapy in menopause: concepts, controversies, and approach to treatment. Endocr Rev 2021; 42:720. doi:10.1210/endrev/bnab011
- Drugs for postmenopausal osteoporosis. Med Lett Drugs Ther 2020; 62:105.
- Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms and prevention of osteoporosis. Med Lett Drugs Ther 2014; 56:33.
- N Santoro et al. Compounded bioidentical hormones in endocrinology practice: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2016; 101:1318. doi:10.1210/jc.2016-1271
- FZ Stanczyk et al. Bioidentical hormones. Climateric 2021; 24:38. doi:10.1080/13697137.2020.1862079
- JP Christ et al. Nonhormonal therapies for menopausal vasomotor symptoms. JAMA 2023; 330:1278. doi:10.1001/jama.2023.15965
- Fezolinetant (Veozah) for menopausal vasomotor symptoms. Med Lett Ther 2023; 65:97.
- K Schaudig et al. Efficacy and safety of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy: the phase 3b DAYLIGHT study. 15th Congress of the European Society of Gynecology (ESG); Amsterdam, The Netherlands; November 29-December 2, 2023. Abstract #12497.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- DL Barton et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010; 28:3278. doi:10.1200/jco.2009.26.6379
- EW Freeman et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305:267. doi:10.1001/jama.2010.2016
- SD Reed et al. Lights on MsFLASH: a review of contributions. Menopause 2020; 27:473. doi:10.1097/gme.0000000000001461
- DJ Portman et al. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopause 2014; 21:1082. doi:10.1097/gme.0000000000000210
- Paroxetine (Brisdelle) for hot flashes. Med Lett Drugs Ther 2013; 55:85.
- D Shan et al. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Am J Obstet Gynecol 2020; 222:564. doi:10.1016/j.ajog.2019.12.011
- H Joffe et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol 2010; 202:171.e1. doi:10.1016/j.ajog.2009.10.868
- RA Leon-Ferre et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr 2019; 4:pkz088. doi:10.1093/jncics/pkz088
- Oxybutynin for hot flashes in women with breast cancer. Med Lett Drugs Ther 2019; 61:30.
- P-P Guo et al. Complementary and alternative medicine for natural and treatment-induced vasomotor symptoms: an overview of systematic reviews and meta-analyses. Complement Ther Clin Pract 2019; 36:181. doi:10.1016/j.ctcp.2019.07.007
- OH Franco et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016; 315:2554. doi:10.1001/jama.2016.8012
- S Dodin et al. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab 2005; 90:1390. doi:10.1210/jc.2004-1148
- M Ghazanfarpour et al. Effects of flaxseed and Hypericum perforatum on hot flash, vaginal atrophy and estrogendependent cancers in menopausal women: a systematic review and meta-analysis. Avicenna J Phytomed 2016; 6:273.
- K Winther et al. Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric 2005; 8:162. doi:10.1080/13697130500117987
- SD Reed et al. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008; 15:51. doi:10.1097/gme.0b013e318057787f
- AC Brown. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 2 of 5 series. Food Chem Toxicol 2017; 107:472. doi:10.1016/j.fct.2016.07.001
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
